Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium
Hydrogels are biocompatible drug delivery systems by which the physical properties can be controlled by the cross-linking density. Hydrogels were prepared by copolymerization of acrylic acid monomers in the presence of poly(ethylene glycol)(PEG) to form polyethylene diacrylate (PEDGA). Various molecular weights of PEGs were used for the synthesis of PEGDA to study the effect of molecular weight of PEG on the properties of hydrogels. These hydrogels were further characterized for free water, swelling..


Pharmaceutical Technology


PEGDA acted as a polymerization template for the polymerization of acrylic acid monomers at both ends, resulting in copolymers where PEG became entangled within the polyacrylate polymeric network. PEGDA is hydrophilic, so with the increase in the ratio of PEGDA in copolymeric structures, the hydrophilicity of the hydrogels increased. This study is different from studies that use the usual other small molecular cross-linkers that are not hydrophilic. These cross-linkers cannot impart any hydrophilicity and at the same time can only increase the compactness of the hydrogel mass by a sewing-like action for end-to-end polymeric compaction with an increase in its amounts within the polymeric networks.The trend in the present study showed that as the hydrophilic nature of PEG decreases with the increase in molecular weight, the hydrophilicity of these copolymeric hydrogels decreased with the increase in molecular weight. For the same weight ratio, the molar percentage of PEGDA decreases with the increase in molecular weight, reducing the hydrophilicity and water-absorbing capacity and swelling tendency of such copolymeric polyacrylates.

Water-diffusion study . The release of a drug from a matrix system usually is governed by diffusion, so determining the diffusion coefficient of the hydrogels is essential. The diffusion coefficient of the swollen hydrogel can be measured fairly easily by either the membrane permeation method or the sorption and desorption method. The membrane permeation time–lag experiment has been widely used; however, it is not always the most practical method (30). In the present work, therefore, desorption phenomenon (32) was used to determine the diffusion coefficient of the prepared hydrogels.


Table III: In vitro characterization of different hydrogel formulations (n* = 3).
The hydrogels showed good diffusion property, with diffusion coefficients of the order 10–6 (see Table III). As the molecular weight of the PEGDA was increased, its molar percentage decreased for the same weight percent. The cross-linking density of the system, therefore, decreased with the increase in the molecular weight of PEGDA, thereby increasing the diffusion coefficient. This is evident from the diffusion coefficient of formulation B15, which was 3.32 × 10–6 cm2 /s, whereas that of B60 was 4.57 × 10–6 cm2 /s. With the increase in molecular weight of PEGDA, the porosity might have increased because of the increase in chain length of the PEG cross-linker. Also, the hydrophilicity of PEGs decrease with the increase in molecular weight (33), so the diffusion of water became easier from systems containing PEGs of higher molecular weight. The diffusion coefficient, however, decreased with an increase in the amount of PEGDA(e.g., that for C15 was found to be 2.24 ×10–6 cm2 /s and that for D15 was 1.86 ×10–6 cm2 /s). This decrease may be attributed to the increase in the amount of hydrophilic PEG, which causes an increase in the difficulty of water diffusion out of the hydrogel matrix.


ADVERTISEMENT

RELATED CONTENT
Roche Recalls Viracept
Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium
The Effect of Core and Coating Composition on Drug Release from Directly Compressed Time-Controlled Release Tablets
Near-Infrared Assay and Content Uniformity of Tablets
Maintain Your Moving Parts
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here